计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| F414250-2mg |
2mg |
现货 ![]() |
| |
| F414250-5mg |
5mg |
现货 ![]() |
| |
| F414250-10mg |
10mg |
现货 ![]() |
| |
| F414250-25mg |
25mg |
现货 ![]() |
| |
| F414250-50mg |
50mg |
现货 ![]() |
| |
| F414250-100mg |
100mg |
现货 ![]() |
|
| 别名 | 1,4-二氢-1-[(2R)-2-(2-甲氧基苯基)-2-[(四氢-2H-吡喃-4-基)氧基]乙基]-alpha,alpha,5-三甲基-6-(2-恶唑基)-2,4-二氧代噻吩并[2,3-d]嘧啶-3(2H)-乙酸 | 菲索科斯塔 (GS-0976) |
|---|---|
| 英文别名 | FIRSOCOSTAT [WHO-DD] | ND-630; NDI-010976; Firsocostat | FIRSOCOSTAT [INN] | BS-15388 | THIENO(2,3-D)PYRIMIDINE-3(2H)-ACETIC ACID, 1,4-DIHYDRO-1-((2R)-2-(2-METHOXYPHENYL)-2-((TETRAHYDRO-2H-PYRAN-4-YL)OXY)ETHYL)-.ALPHA.,.ALPHA.,5-TRIMETHYL-6-(2-OXAZOLYL)-2 |
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Firsocostat (GS-0976) |
| 生化机理 | Firsocostat(GS-0976,NDI-010976,ND-630)是乙酰辅酶羧化酶(ACC)的可逆抑制剂,对 hACC1 和 hACC2 的 IC50 分别为 2.1 nM 和 6.1 nM。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 变构调节剂 |
| 作用机制 | 乙酰辅酶羧化酶 1 的异构调节剂;乙酰辅酶羧化酶 2 的异构调节剂 |
| 产品介绍 |
Firsocostat (GS-0976, NDI-010976, ND-630)是acetyl CoA carboxylase (ACC)的一种可逆抑制剂,对hACC1和hACC2的IC50分别为2.1 nM,6.1 nM。 Information Firsocostat (GS-0976) Firsocostat (GS-0976, NDI-010976, ND-630) is a reversible inhibitor of acetyl CoA carboxylase (ACC) with IC50s of 2.1 nM,6.1 nM for hACC1 and hACC2,respectively. Targets hACC1 (Cell-free assay); hACC2 (Cell-free assay) 2.1 nM; 6.1 nM In vitro When ND-630 and [14C]acetate were administered to Hep-G2 cells for 4 h, ND-630 inhibited FASyn with EC50 values of 66 nM in cells cultured in medium containing. When ND-630 and[14C]palmitate were administered to C2C12 cells for 6 h, ND-630 increased both the release of [14C]O2 and the production of[14C]acid-soluble material. In vivo When administered chronically to rats with diet-induced obesity, ND-630 reduces hepatic steatosis, improves insulin sensitivity, reduces weight gain without affecting food intake, and favorably affects dyslipidemia. |
| 纯度 | ≥98% |
| ALogP | 2.946 |
|---|---|
| hba_count | 8 |
| Rotatable Bond | 9 |
| PubChem SID | 504772151 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 2-[1-[(2R)-2-(2-methoxyphenyl)-2-(oxan-4-yloxy)ethyl]-5-methyl-6-(1,3-oxazol-2-yl)-2,4-dioxothieno[2,3-d]pyrimidin-3-yl]-2-methylpropanoic acid |
| INCHI | 1S/C28H31N3O8S/c1-16-21-24(32)31(28(2,3)26(33)34)27(35)30(25(21)40-22(16)23-29-11-14-38-23)15-20(39-17-9-12-37-13-10-17)18-7-5-6-8-19(18)36-4/h5-8,11,14,17,20H,9-10,12-13,15H2,1-4H3,(H,33,34)/t20-/m0/s1 |
| InChi Key | ZZWWXIBKLBMSCS-FQEVSTJZSA-N |
| Smiles | CC1=C(SC2=C1C(=O)N(C(=O)N2CC(C3=CC=CC=C3OC)OC4CCOCC4)C(C)(C)C(=O)O)C5=NC=CO5 |
| Isomeric SMILES | CC1=C(SC2=C1C(=O)N(C(=O)N2C[C@@H](C3=CC=CC=C3OC)OC4CCOCC4)C(C)(C)C(=O)O)C5=NC=CO5 |
| 分子量 | 569.63 |
| Reaxy-Rn | 23529544 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=23529544&ln= |
| 溶解性 | Solubility (25°C) In vitro DMSO: 100 mg/mL (175.55 mM); Ethanol: 4 mg/mL (7.02 mM); Water: Insoluble; |
|---|---|
| DMSO(mg / mL) Max Solubility | 100 |
| DMSO(mM) Max Solubility | 175.552551656338 |
| Water(mg / mL) Max Solubility | <1 |
| 分子量 | 569.600 g/mol |
| XLogP3 | 3.200 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 10 |
| 可旋转键计数Rotatable Bond Count | 9 |
| 精确质量Exact Mass | 569.183 Da |
| 单同位素质量Monoisotopic Mass | 569.183 Da |
| 拓扑极表面积Topological Polar Surface Area | 160.000 Ų |
| 重原子数Heavy Atom Count | 40 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 947.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 1 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS07 |
|---|---|
| 信号词 | 警告 |
| 危险声明 |
H302: 吞食有害 H315: 引起皮肤刺激 H319: 引起严重眼睛刺激 H335: 可能引起呼吸道刺激 |
| 预防措施声明 |
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾 P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。 |
| 1. Harriman G, Greenwood J, Bhat S, Huang X, Wang R, Paul D, Tong L, Saha AK, Westlin WF, Kapeller R et al.. (2016) Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats.. Proc Natl Acad Sci USA, 113 (13): (E1796-805). [PMID:26976583] |
| 2. Loomba R, Kayali Z, Noureddin M, Ruane P, Lawitz EJ, Bennett M, Wang L, Harting E, Tarrant JM, McColgan BJ et al.. (2018) GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.. Gastroenterology, 155 (5): (1463-1473.e6). [PMID:30059671] |
| 3. Alkhouri N, Lawitz E, Noureddin M, DeFronzo R, Shulman GI. (2020) GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH).. Expert Opin Investig Drugs, 29 (2): (135-141). [PMID:31519114] |
| 4. Alkhouri N. (2020) NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges.. Expert Opin Investig Drugs, 29 (2): (87). [PMID:31984804] |
| 5. Matsumoto M, Yashiro H, Ogino H, Aoyama K, Nambu T, Nakamura S, Nishida M, Wang X, Erion DM, Kaneko M. (2020) Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis.. PLoS ONE, 15 (1): (e0228212). [PMID:31990961] [10.1371/journal.pone.0228212] |
| 6. Kayampilly P, Roeser N, Rajendiran TM, Pennathur S, Afshinnia F. (2022) Acetyl Co-A Carboxylase Inhibition Halts Hyperglycemia Induced Upregulation of De Novo Lipogenesis in Podocytes and Proximal Tubular Cells.. Metabolites, 12 (10): [PMID:36295842] [10.3390/metabo12100940] |